COVID-19 vaccine development, enrollment and funding status July 28, 2020, by company

By the end of the year, over 180,000 individuals are expected to take part in phase 3 clinical trials for vaccinations against coronavirus. Of the six trials listed, four have acquired U.S. taxpayer funding through the Biomedical Advanced Research and Development Authority (BARDA) or "U.S. Project Warp Speed". This statistic shows the number of expected phase 3 participants and BARDA/Warp Speed funding status of selected COVID-19 vaccines, by company, as of July 28, 2020.

截至本年度末，预计将有超过18万人参与针对冠状病毒疫苗接种的第三期临床试验。在列出的六项试验中，其中四项已通过美国生物医学高级研究与开发管理局（BARDA）或称“美国项目闪电战”获得了美国纳税人的资金支持。此统计数据展示了截至2020年7月28日，按公司分类的预期第三期参与者数量以及选定的COVID-19疫苗的BARDA/闪电战资助状况。